10 Best Trucking Stocks To Invest In Right Now

Following the announcement earlier this year of its intention to buy several bakeries, depots, and brand names as part of Hostess’ bankruptcy proceedings, Flowers Foods (NYSE: FLO  ) has completed the $355 million deal, the company announced yesterday.

In addition to 20 bakeries, Flowers Foods’ acquisition also includes rights for iconic bread brand names including Wonder, Home Pride, Butternut, Merita, and Nature’s Pride. The $355 million deal also calls for Flowers Foods to assume ownership of 36 former Hostess Brands depots.

Flowers Foods president and CEO Allen Shiver commented on the deal in a statement, saying, “These assets fit very well with our strategy to grow our fresh baked foods through market expansion and acquisitions. Consumers across much of the country can expect to see these well-known and loved bread brands returning to store shelves over time.”

Flowers Foods had initially offered $360 million for the Hostess assets, however, the two sides agreed to an adjustment related to the Butternut trademark, according to the company, and settled on $355 million.

10 Best Trucking Stocks To Invest In Right Now: Triple-S Management Corporation (GTS)

Triple-S Management Corporation, through its subsidiaries, offers a portfolio of managed care and related products in the commercial and Medicare markets in Puerto Rico. The company operates in three segments: Managed Care, Life Insurance, and Property and Casualty Insurance. It provides managed care products, including health maintenance organization plans; preferred provider organization plans; Medicare Supplement products; Medicare Advantage products; Medicaid plans; and Medicare Part D, a prescription drug plan; and claims processing and other administrative services. The company offers its managed care products to employers, professional and trade associations, individuals, and government entities. It also provides various life, accident, disability, and health and annuity insurance products to individuals; and property and casualty insurance products, which include commercial multi-peril, commercial property mono-line, auto physical damage, auto liability, and dwelli ng policies to commercial customers. The company markets its products through a network of internal sales force, direct mail, independent brokers and agents, telemarketing staff, and the Internet. Triple-S Management Corporation was incorporated in 1997 and is based in San Juan, Puerto Rico.

Advisors’ Opinion:

  • [By Brian Pacampara]

    What: Shares of Puerto Rican managed-care company Triple-S Management (NYSE: GTS  ) popped 11% today after its quarterly results topped Wall Street expectations.

10 Best Trucking Stocks To Invest In Right Now: Givaudan SA (GIVN)

Givaudan SA is a Switzerland-based holding company engaged in the fragrance and flavor industry. The Company has two business divisions: Fragrances and Flavors. The Fragrances business segment comprises the manufacture and sale of fragrances into three global business units: Fine Fragrances, comprising signature fragrances and line extensions, Consumer Products, comprising fabric and personal care, hair and skin care, household and air care, as well as oral care, and Fragrance Ingredients. The Flavors business division comprises the manufacture and sale of flavors into four business units: Beverages, comprising flavors for soft drinks, fruit juices and instant beverages; Dairy, comprising ice cream, yoghurt, desserts and yellow fats; Savory, covering soups and sauces, among others; and Confectionery. The Company is also engaged in research and development activities, which comprises the development of a palette of perfumery raw materials, both synthetic and natural. Advisors’ Opinion:

  • [By Inyoung Hwang]

    Berkeley Group Holdings Plc (BKG) surged 8.3 percent after saying first-half profit rose 22 percent. London Stock Exchange Group Plc (LSE) climbed 2.4 percent after Bank of America Corp.’s Merrill Lynch unit recommended buying the stock. Givaudan SA (GIVN) lost 1.3 percent after Nestle SA said it will sell $1.27 billion of shares in the world’s largest flavorings maker.

  • [By Celeste Perri]

    Nestle SA (NESN) is selling Givaudan (GIVN) SA shares worth $1.27 billion at yesterday’s closing price to institutional investors, winding down its stake in the world’s largest flavorings maker.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Given Imaging (Nasdaq: GIVN  ) , whose recent revenue and earnings are plotted below.

10 Best Trucking Stocks To Invest In Right Now: support.com Inc.(SPRT)

Support.com, Inc. provides online care services for the digital home and small business primarily in North America. Its services and software products install, set up, connect, repair, and protect personal computers (PCs) and related devices that are essential to its customers; and it offers it as one-time services and subscriptions, and as software products to consumers who prefer do-it-yourself solutions. The company?s online care services include installation and setup services; connect and secure services that configure, connect, and establish secure connections between the computer, the wireless network, and supported devices; diagnose and repair services to identify, diagnose, and repair technical problems comprising the removal of viruses, spyware, and other forms of malware; and mobile device services. Its online care services also consist of tune-up services, which optimizes key systems settings for faster start-up and shut-down, loading of programs, and Internet browsing; online data backup; and server and network monitoring and management, hosted email and virtual desktops, and disaster recovery services. In addition, the company offers various software products, such as Advanced Registry Optimizer to identify and repair errors in the registry database on PCs; Cosmos software to maintain and optimize the performance of PCs; Hard Disk Tune-Up that improves the performance of a computer by defragmenting programs and data stored on the hard drive; MemTurbo, which increases available memory and improves PC performance; RapidStart software for removing or delaying unnecessary startup programs, processes, and services; and SUPERAntiSpyware software, an anti-malware technology. It provides its products and services through its channel partners and directly to consumers. The company was formerly known as SupportSoft, Inc. and changed its name to Support.com, Inc. in June 2009. Support.com, Inc. was founded in 1997 and is headquartered in R edwood City, California.

Advisors’ Opinion:

  • [By Steve Symington]

    What: Shares of Support.com (NASDAQ: SPRT  ) plunged 26% during intraday trading Thursday after the company beat expectations with its third-quarter results, but outlined disappointing support program changes which will negatively affect its business at Comcast in 2014.

  • [By Roberto Pedone]

    Support.com (SPRT) is a provider of online care for the digital home and small business. This stock closed up 2.7% to $5.89 in Tuesday’s trading session.

    Tuesday’s Range: $5.67-$5.92

    52-Week Range: $3.67-$6.28

    Thursday’s Volume: 304,000

    Three-Month Average Volume: 377,189

    From a technical perspective, SPRT spiked higher here right above its 50-day moving average of $5.51 with decent upside volume. This move also pushed shares of SPRT into breakout territory, since the stock took out some near-term overhead resistance at $5.80. Shares of SPRT have been uptrending for the last month, with the stock moving higher from its low of $5.01 to its intraday high of $5.92. During that uptrend, shares of SPRT have been consistently making higher lows and higher highs, which is bullish technical price action.

    Traders should now look for long-biased trades in SPRT as long as it’s trending above its 50-day at $5.51 or above more near-term support at $5.43 and then once it sustains a move or close above Tuesday’s high of $5.92 to its 52-week high at $6.28 with volume that hits near or above 377,189 shares. If that breakout triggers soon, then SPRT will set up to enter new 52-week-high territory above $6.28, which is bullish technical price action. Some possible upside targets off that move are $7 to $8.

10 Best Trucking Stocks To Invest In Right Now: Medical Marijuana Inc (MJNA.PK)

Medical Marijuana Inc. (MJNA), incorporated on May 23, 2005, is the publicly held company vested in the medical marijuana and industrial hemp markets. The Company is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries. These products range from patented based cannabinoid products, to whole plant or isolated high value extracts specifically manufactured and formulated for the pharmaceutical, nutraceutical and cosmeceutical industries. In March 2013, it sold certain equipment and inventory, web domain names, phone numbers, and all existing and pending agreements with hemp production and processing facilities to CannaVEST Corp.

The Company’s services are varied, ranging from medical clinic management to the capitalization and development of existing industry business and product leaders. Services include development of cannabinoid based health and wellness products, and the development of medical grade compounds. MJNA provides over 50 and patented cannabinoid delivery methods that are more socially and medically acceptable than smoking.

Advisors’ Opinion:

  • [By Alan Brochstein]

    Taking into account all of the data I have shared, I want to introduce my take on the most important names to follow. My initial list takes into account not only the market cap, but also business model and interest level. These are the stocks that I think merit the most attention (in alphabetical order):

    CannaVest (CANV.OB)GW Pharma (GWPH)MedBox (MDBX.PK)Medical Marijuana, Inc. (MJNA.PK)

    CANV doesn’t really trade, as it is held closely by insiders (99.7%, including MJNA). I have a few concerns, including the valuation and some near-term financial challenges typical of a start-up with just one client looking to expand its customer base, but I like the focus and the fact that it is an SEC filer with a relatively clean history (i.e. none of the baggage of some of these other companies). I have spoken to its outsourced CFO and am impressed by his background (has been CFO or held key financial roles at publicly-traded healthcare companies). CANV is the partner to MJNA that is responsible for manufacturing the CBD (Cannibidiol, the cannabinoid in marijuana that is increasingly viewed as offering substantial medical benefits). I am very concerned about the near-term financials, but this is a pure-play with probably a two-year lead over other companies. I don’t see a moat in terms of intellectual property or brands, but they have a good lead in terms of sourcing of supply and penetration into potential customers. Quite simply, they don’t appear to have competition at present. The company, then, is a call option on CBD demand taking off. It appears that it could be a supplier to even Big Pharma should medical marijuana research move into the mainstream.

10 Best Trucking Stocks To Invest In Right Now: Beam Inc (BEAM)

Beam Inc. (Beam), incorporated on October 1, 1985, is a premium spirits company that makes and sells branded distilled spirits products in markets worldwide. The Company’s principal products include bourbon whiskey, tequila, Scotch whisky, Canadian whisky, vodka, cognac, rum, cordials, and ready-to-drink pre-mixed cocktails. The Company’s portfolio consists of brands the Company identifies as Power Brands, Rising Stars, Local Jewels and values Creators. The Power Brands are the Company’s core brand equities, with global reach in premium categories. Rising Stars are smaller premium brands. Brands identified as Local Jewels act as Power Brands in local markets. Value Creators include a variety of brands. The Company’s three reportable segments are the geographic regions, which consists of North America, Europe/Middle East/Africa (EMEA), and Asia-Pacific/South America (APSA). Each segment is engaged in the manufacture and sale of distilled spirits products. In May 2012, the C ompany acquired the Pinnacle vodka and Calico Jack rum brands and certain related assets (Pinnacle assets) from White Rock Distilleries, Inc. In January 2012, Beam acquired Cooley Distillery plc (Cooley), an Irish whiskey producer.

The Company’s Power Brands include Jim Beam Bourbon, Maker’s Mark Bourbon, Sauza Tequila, Courvoisier Cognac, Canadian Club Whisky, Teacher’s Scotch and Pinnacle Vodka. Beam’s Rising Stars brand includes Laphroaig Scotch, Knob Creek Bourbon, Basil Hayden’s Bourbon, Kilbeggan Irish Whiskey, Cruzan Rum, Hornitos Tequila, Skinnygirl Cocktails and Sourz Liqueurs. The principal markets for the Company’s spirits products are the United States, Australia, Germany, Spain, the United Kingdom, and Canada, and the Company continues to invest in emerging markets such as India, Brazil, Mexico, Russia, Central Europe, Asia, and other geographies.

During the year ended December 31, 2012, Power Brands, Rising Stars, and combined Loc al Jewels/Value Creators (including non-branded sales) repre! sent approximately 60%, 15%, and 25%, respectively, of the Company’s net sales. Approximately 55% of its consolidated net sales were generated in the United States (based on country of destination) during 2012. In the United States, the Company sells its products either to wholesale distributors for resale to retail outlets or, in those states that control alcohol sales, to state governments who then sell them to retail customers and consumers. In the Company’s other global markets, the Company uses a variety of route-to-market models, including third party distributors, global or regional duty free customers, other spirits producers and its joint ventures with The Edrington Group Ltd.

The Company competes with Bacardi Limited, Brown-Forman Corporation, Constellation Brands, Inc., Davide Campari Milano-S.p.A., Diageo PLC, Pernod Ricard S.A. and Remy Cointreau S.A.

Advisors’ Opinion:

  • [By Joseph Gacinga]

    Another notable case is the spinoff of Fortune Brands Home & Security (NYSE: FBHS  ) from Beam (NYSE: BEAM  ) in 2011. Fortune Brands Home & Security shares have climbed at a much faster clip than Beam’s shares since then.

  • [By Patricio Kehoe]

    When Diageo’s CEO Ivan Menezes declared last quarter that the company would not be buying Beam Inc. (BEAM) in order to boost its bourbon and tequila portfolio, it became clear that the firm was well off as it is. And I applaud management’s decision to hold back, because this firm’s unmatched spirit portfolio combined with its vast distribution network make it a solid global market leader. Although the company operates in 180 countries, its particularly strong position in the U.S. market is highly beneficial, as this is the most profitable spirits market worldwide. The distribution, handled by 2,800 exclusive salespeople that only attend the company’s namesake brands, is highly profitable, resulting in domestic operating margins of almost 40%. Also, these distributor relationships cover 80% of the company’s U.S. volume, making for a business model that would be very difficult for new market entrants to duplicate.

  • [By Anna Prior]

    Beam Inc.(BEAM) said that federal antitrust regulators have given clearance for the spirits company’s takeover by Suntory Holding Ltd. Beam said Wednesday that the U.S. Federal Trade Commission has granted early termination of the necessary waiting period to review Beam’s proposed acquisition by Suntory.

10 Best Trucking Stocks To Invest In Right Now: Trans World Entertainment Corp.(TWMC)

Trans World Entertainment Corporation, through its subsidiaries, operates as a specialty retailer of entertainment software products, including music, video, video games, and other related products through its retail stores and e-commerce sites in the United States. The company?s other related products include electronics, accessories, and trend items. As of January 29, 2011, it operated 376 mall-based stores under the For Your Entertainment (f.y.e.), Suncoast Motion Pictures, and Saturday Matinee brand names in regional shopping malls; 84 freestanding stores under the f.y.e. brand name; and 3 retail Websites, including fye.com, wherehouse.com, and secondspin.com. The company operates retail stores in the United States, the District of Columbia, the Commonwealth of Puerto Rico, and the U.S. Virgin Islands. Trans World Entertainment Corporation was founded in 1972 and is headquartered in Albany, New York.

Advisors’ Opinion:

  • [By Tim Melvin]

    The safe and cheap undervalued stocks will go right up, but your chances of being destroyed when the party is over are diminished. Stocks like Richardson Electronics (RELL) and Transworld Entertainment (TWMC) have the ability to go up as the market bubbles higher but their asset value will act as sort of a floor in a decline.

10 Best Trucking Stocks To Invest In Right Now: GlaxoSmithKline PLC(GSK)

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, vaccines, and dermatologicals. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets a range of vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company provides OTC medicines, including Panadol, a paracetamol-based treatment of headache and joi nt pain, fever, and cold symptoms; Gaviscon, a range of antacid products that relieve heartburn due to acid reflux; and NicoDerm, NiQuitin CQ, Nicabate, and Nicorette for the treatment of nicotine withdrawal as an aid to quit smoking. Further, it offers oral healthcare products comprising Sensodyne, a range of toothpastes and toothbrushes for the prevention of dental sensitivity; Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; and Polident, Poligrip, and Corega, which are denture adhesives and cleansers. Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks for energy and hydration; Horlicks, a malted, milk-based drink and food for nutrition application; and Ribena, an apple, orange, raspberry, and pomegranate flavored fruit drink, as well as markets skincare products. GlaxoSmithKline plc was incorporated in 1999 and is headquartered in Brentford, United Kingdom.

Advisors’ Opinion:

  • [By Arrow Analysis]

    Acquiring AstraZeneca has a lot of potential benefits for Pfizer. For one, this merger would make Pfizer the largest pharmaceutical company in terms of revenue gain. With the announcement of the recent three way deal between GlaxoSmithKline (GSK), Novartis (NVS) and Eli Lilly (LLY), Pfizer Inc desperately needs something to keep investors interested – and for the right reasons.

  • [By Holly LaFon]

    Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than original cost. As stated in the current prospectus, the Fund’s Investor Class Share’s annual operating expense ratio (gross) is 1.28%. The Fund’s adviser has contractually agreed to waive a portion of its fee and/or reimburse Fund expenses to limit total annual operating expenses at 1.25%, which is in effect until October 31, 2015. Other share classes may vary. The Fund charges a 2.0% redemption fee on shares redeemed within six months of purchase. For the most recent month-end performance, please call (877)328-9437 or visit the Advisor’s website at www.auxierasset.com. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future.Spring 2014 Market CommentaryAuxier Focus Fund’s Investor Class returned a modest 0.25% for the quarter ended March 31, while Standard and Poor’s 500 Stock Index (S&P) rose 1.81%. The Fund ended the quarter with 70% in U.S. stocks, 16% foreign stocks, 1.7 % bonds and 12.3% cash. Since inception in 1999, the Fund’s equity exposure has averaged 72%. Our stockholdings in the healthcare industry generally gained for the quarter. But many of our multinational and foreign stocks were hurt by the threat of currency repercussions from geopolitical events in Russia and Ukraine. The foreign portion of the Fund is easily the most undervalued. Longer term, we see a very favorable risk/reward potential with our UK and European holdings. Some emerging market companies we follow are the cheapest in over twenty years. In allocating capital, we much prefer the gloom of down to flat markets and the corrective process that tempers exuberance. We re member that one of th

10 Best Trucking Stocks To Invest In Right Now: Shire PLC (SHPG)

Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company’s products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31 , 2012, the Company’s products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.

VANSE/ VENVANSE

VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutic ally inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.

ADDERALL XR

ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram caps ules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax’s sales of authorized generic ADDERALL XR.

INTUNIV

INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once- daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.

EQUASYM

Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.

LIALDA/MEZAVANT

LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.

PENTASA

PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.

RESOLOR

RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointesti nal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.

XAGRID

XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.

REPLAGAL

REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.

ELAPRASE

ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body’s ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.

VPRIV

VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.

FIRAZYR

FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.

DERMAGRAFT

DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.

The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.

Advisors’ Opinion:

  • [By Jesse Solomon]

    A flurry of acquisitions has already occurred in the past few years. Most recently, the Irish pharmaceutical conglomerate Shire (SHPG) bought Pennsylvania-based ViroPharma for $4.2 billion late last year. The deal gave Shire access to Cinryze, medicine for a rare blood disorder.

  • [By George Budwell]

    Shire plc (NASDAQ: SHPG  ) is in the process of buying orphan drug-specialist ViroPharma (NASDAQ: VPHM  ) for $4.2 billion, strengthening Shire’s already robust commercial drug portfolio for rare diseases. The deal is expected to be finalized no later than Jan. 9, after Shire extended its tender offer to acquire all outstanding ViroPharma shares last week.

10 Best Trucking Stocks To Invest In Right Now: Catalyst Pharmaceutical Partners Inc.(CPRX)

Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor candidate, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including drug addiction, epilepsy, and for other selected central nervous disease indications. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide, as well as a definitive clinical trial agreement with the National Institute on Drug Abuse to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109 for the treatment of cocaine addiction. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Advisors’ Opinion:

  • [By Roberto Pedone]

    One under-$10 biopharmaceutical player that’s starting to move within range of triggering a big breakout trade is Catalyst Pharmaceutical Partners (CPRX), which is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock has been on fire so far in 2013, with shares up a whopping 364%.

    If you take a look at the chart for Catalyst Pharmaceutical Partners, you’ll notice that this stock has been uptrending strong for the last month, with shares soaring higher from its low of $1.29 to its intraday high of $2.09 a share. During that uptrend, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed share of CPRX within range of triggering a big breakout trade.

    Traders should now look for long-biased trades in CPRX if it manages to break out above its 50-day moving average of $2.11 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 2.21 million shares. If that breakout triggers soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3 a share. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65 a share.

    Traders can look to buy CPRX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.65 to $1.63 a share. One can also buy CPRX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By Roberto Pedone]

    Catalyst Pharmaceutical Partners (CPRX) is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock closed flat to $1.87 in Tuesday’s trading session.

    Tuesday’s Range: $1.78-$1.98

    52-Week Range: $0.41-$3.65

    Tuesday’s Volume: 1.62 million

    Three-Month Average Volume: 2.20 million

    From a technical perspective, CPRX closed off its intraday low of $1.78 to $1.87 with lighter-than-average volume. This stock has been uptrending for the last few weeks, with shares moving higher from its low of $1.29 to its recent high of $2.07. During that move, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CPRX within range of triggering a near-term breakout trade. That trade will hit if CPRX manages to take out some near-term overhead resistance levels at $2.07 to its 50-day moving average of $2.16 with high volume.

    Traders should now look for long-biased trades in CPRX as long as it’s trending above some near-term support at $1.63 and then once it sustains a move or close above those breakout levels with volume that’s near or above 2.20 million shares. If that breakout hits soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65.

  • [By John Udovich]

    While the Twitter IPO has been grabing everyone’s attention, biotech IPOs continue to dominate both biotech and IPO news with Karyopharm Therapeutics Inc (NASDAQ: KPTI) going public yesterday and Relypsa (NASDAQ: RLYP), TetraLogic Pharmaceuticals (NASDAQ: TLOG), Vital Therapies (NASDAQ: VTL) and Xencor (NASDAQ: XNCR) filing to go public in the near future (despite the sector producing some ugly charts for the month of October) plus another small cap called TNI BioTech (OTCMKTS: TNIB) has also been producing a steady flow of news:

    Karyopharm Therapeutics Debuts. Yesterday, small cap Karyopharm Therapeutics, which is working on a drug that aids the body’s natural tumor-suppressing proteins, debuted at the top of its range to raise $109 million in an upsized offering of 6.8 million shares at $16 apiece with shares closing at $16.81. It should be noted that Karyopharm Therapeutics’ lead drug candidate (Selinexor) is in early-stage clinical trials and the company lost lost nearly $12.5 million on revenue of $366,000 during the first six months of this year. Biotech IPOs by Region. On an interesting note, Luke Timmerman, the National Biotech Editor of Xconomy, has written a good article tracking biotech or life sciences IPOs by region. By his count, Boston is home to eight of the 45 (18%) of the life sciences IPOs this year (its companies have also raised the most money – about $770 million) plus the New York/northern New Jersey region is also home to eight. San Diego came in third with six IPOs followed by San Francisco with five while only five of the 45 biotech IPOs came from outside the US (Three from Israel and two from Europe). However, the above figures may change as by his account, there are 15 additional biotech companies in line to go public. More Biotechs Set IPO Terms. The small cap biotech space is about to be joined by a few new additions as a couple of biotechs file to go public over the past week or so: Relypsa, which is d

10 Best Trucking Stocks To Invest In Right Now: Deutsche Boerse AG (DB1)

Deutsche Boerse AG is a Germany-based international financial marketplace operator. It operates four business segments: Xetra; Eurex; Clearstream, and Market Data & Analytics. The Xetra business segment comprises three business areas: cash market using the Xetra electronic trading system and Xetra Frankfurt specialist trading; central counterparty for equities, and admission of securities to listing. The Eurex business segment comprises four business areas: electronic derivatives market trading platform Eurex; electronic options trading platform ISE; over-the-counter trading platforms Eurex Bonds, Eurex Repo, and Eurex Clearing. The Clearstream business segment comprises three business areas: custody, administration and settlement services for securities; global securities financing services, and investment funds services. The Market Data & Analytics business segment comprises two business areas: sales of price information and information distribution, and index development a nd sales. Advisors’ Opinion:

  • [By Nikolaj Gammeltoft]

    The mishap followed others earlier in the week. An Oct. 30 malfunction interrupted data transmission at Deutsche Boerse AG (DB1)’s International Securities Exchange, while Nasdaq was unable to distribute prices for its benchmark stock indexes for almost an hour on Oct. 29. The breakdowns refocused concern that the distribution of trading over dozens of mostly automated venues has made U.S. securities markets fundamentally flawed.

  • [By Jonathan Morgan]

    QSC AG (QSC), a provider of telephony and data services to small and medium-sized businesses, jumped 9.5 percent after posting an increase in quarterly net income. Deutsche Boerse AG (DB1) retreated 2.7 percent after Equinet Bank AG downgraded the shares to sell.

  • [By Nikolaj Gammeltoft]

    IntercontinentalExchange, the energy and commodity futures bourse known as ICE, is buying the U.S. equity exchange operator as the profitability of stock trading declines and derivatives generate more income. European Union regulators approved the deal on June 24 after blocking Deutsche Boerse AG (DB1)’s purchase of NYSE last year, citing concern over competition in derivatives and clearing.